Manitimus

Manitimus is an inhibitor of dehydroorotate dehydrogenase, and a potent immunosuppressive drug.

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

In the Manitimus-treated rats, there is a dose-related, differential effect: mean survival is 15.7 days in group 4 (Manitimus 5 mg/kg), 19.1 days in group 5 (Manitimus 10 mg/kg) and 25.4 days in group 6 (Manitimus 20 mg/kg)[1]. Manitimus (15 mg/kg, p.o.) results in a significant decrease in neointimal area and percentage of stenosis versus the control rats, and diminishes the effect that CMV infection results in a significant increase in intimal and medial cross-sectional area and medial wall thickness of the vein grafts[2].

The whole experiment consists of a total of four experimental groups (n = 10 animals/group) which all undergo surgery. Furthermore, rats are either infected with CMV, treated with Manitimusor both. A control group only receive the Manitimus solvent (1 mL of a 1% carboxymethylcellulose solution in water). Infection is established by inoculating rats intraperitoneally with 1.25×106 plaque-forming units of homogenized salivary gland-derived rat CMV immediately after surgery.

[1]. Birnbaum F, et al. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model. Eye (Lond). 2007 Dec;21(12):1516-23. Epub 2007 Mar 30.

[2]. Kloppenburg G, et al. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model. Intervirology. 2009;52(4):189-95.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline